Jennifer Edelman, MD, MHS
Yale School of Medicine
This study leverages the Project ED Health study (CTN-0069) to assess the impact of the COVID-19 epidemic on opioid use and treatment and COVID-19 symptoms and testing. Specifically, the investigators seek to characterize the impact of the COVID-19 pandemic on (Aim 1) OUD treatment (engagement and access to MOUD), drug use, drug supply, and overdose risk, (Aim 2) COVID-19 related symptoms and testing, and (Aim 3) ED leadership reports of the presentation of patients with OUD to the ED, ED-based buprenorphine prescribing practices, and community treatment options.
- CTN-0069: Opioid Use Disorder in the Emergency Department (Project ED Health)
- CTN-0069-A-1: Retrospective Evaluation of Rapid Buprenorphine Induction in the Emergency Department for Opioid Use Disorder
All Participating Nodes: